Inhibition of renal fibrosis with a human CXCL9‐derived glycosaminoglycan‐binding peptide

Renal fibrosis accompanies all chronic kidney disorders, ultimately leading to end‐stage kidney disease and the need for dialysis or even renal replacement. As such, renal fibrosis poses a major threat to global health and the search for effective therapeutic strategies to prevent or treat fibrosis is highly needed. We evaluated the applicability of a highly positively charged human peptide derived from the COOH‐terminal domain of the chemokine CXCL9, namely CXCL9(74–103), for therapeutic intervention. Because of its high density of net positive charges at physiological pH, CXCL9(74–103) competes with full‐length chemokines for glycosaminoglycan (GAG) binding. Consequently, CXCL9(74–103) prevents recruitment of inflammatory leucocytes to sites of inflammation.

[1]  V. Tesar,et al.  Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal , 2019, Kidney and Blood Pressure Research.

[2]  F. Tacke,et al.  Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. , 2019, Molecular aspects of medicine.

[3]  G. Opdenakker,et al.  Anti‐inflammatory effects of the GAG‐binding CXCL9(74‐103) peptide in dinitrofluorobenzene‐induced contact hypersensitivity in mice , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  P. Proost,et al.  The chemokine fragment CXCL9(74–103) diminishes neutrophil recruitment and joint inflammation in antigen‐induced arthritis , 2018, Journal of leukocyte biology.

[5]  Yau-Huei Wei,et al.  Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves’ orbital fibroblasts , 2018, Scientific Reports.

[6]  N. Vaziri,et al.  Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  P. Proost,et al.  Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands , 2018, Front. Immunol..

[8]  M. Mack Inflammation and fibrosis. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[9]  P. Boor,et al.  PDGF in organ fibrosis. , 2017, Molecular aspects of medicine.

[10]  P. Ryan,et al.  CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study , 2017, Clinical and Translational Medicine.

[11]  P. Proost,et al.  Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling , 2017, International journal of molecular sciences.

[12]  Paul Martin,et al.  Inflammation and metabolism in tissue repair and regeneration , 2017, Science.

[13]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[14]  P. Kubes,et al.  CXCL9-Derived Peptides Differentially Inhibit Neutrophil Migration In Vivo through Interference with Glycosaminoglycan Interactions , 2017, Front. Immunol..

[15]  S. Samsonov,et al.  Sulfated Hyaluronan Derivatives Modulate TGF-β1:Receptor Complex Formation: Possible Consequences for TGF-β1 Signaling , 2017, Scientific Reports.

[16]  C. Chung,et al.  Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis , 2016, International journal of nanomedicine.

[17]  P. Proost,et al.  Basic chemokine-derived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus. , 2016, Biochemical pharmacology.

[18]  A. Fabre,et al.  CXCL9 Regulates TGF-β1–Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells , 2015, The Journal of Immunology.

[19]  P. Proost,et al.  The Positively Charged COOH-terminal Glycosaminoglycan-binding CXCL9(74–103) Peptide Inhibits CXCL8-induced Neutrophil Extravasation and Monosodium Urate Crystal-induced Gout in Mice* , 2015, The Journal of Biological Chemistry.

[20]  P. E. Van den Steen,et al.  CXCR3 ligands in disease and therapy. , 2015, Cytokine & growth factor reviews.

[21]  A. Kungl,et al.  A Combinatorial Approach to Biophysically Characterise Chemokine-Glycan Binding Affinities for Drug Development , 2014, Molecules.

[22]  E. Tredget,et al.  The Role of Chemokines in Fibrotic Wound Healing. , 2014, Advances in wound care.

[23]  Douglas B. Evans,et al.  Chemokines and chemokine receptors: update on utility and challenges for the clinician. , 2014, Surgery.

[24]  S. Rennard,et al.  Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[25]  W. Teughels,et al.  Citrullination and Proteolytic Processing of Chemokines by Porphyromonas gingivalis , 2014, Infection and Immunity.

[26]  J. Van Damme,et al.  CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase , 2014, Angiogenesis.

[27]  A. Mantovani,et al.  International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors , 2014, Pharmacological Reviews.

[28]  H. Wasmuth,et al.  Chemokines in tissue fibrosis. , 2013, Biochimica et biophysica acta.

[29]  S. Alexander,et al.  Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage , 2013, Laboratory Investigation.

[30]  S. Friedman,et al.  Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.

[31]  M. Trinker,et al.  Targeting chemokine-glycan interactions: the CellJammer(®) technology platform. , 2012, Drug discovery today. Technologies.

[32]  Youliang Wang,et al.  Renal tubular epithelial cell injury, apoptosis and inflammation are involved in melamine-related kidney stone formation , 2012, Urological Research.

[33]  P. Proost,et al.  Overview of the mechanisms regulating chemokine activity and availability. , 2012, Immunology letters.

[34]  B. Thornhill,et al.  Fight-or-flight: murine unilateral ureteral obstruction causes extensive proximal tubular degeneration, collecting duct dilatation, and minimal fibrosis. , 2012, American journal of physiology. Renal physiology.

[35]  Fabian Kiessling,et al.  Chemokine Cxcl9 attenuates liver fibrosis‐associated angiogenesis in mice , 2012, Hepatology.

[36]  R. Kalluri,et al.  Mechanistic connection between inflammation and fibrosis. , 2010, Kidney international. Supplement.

[37]  R. Homer,et al.  Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.

[38]  M. T. Grande,et al.  Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy , 2010, Journal of Inflammation.

[39]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[40]  A. Rek,et al.  Therapeutically targeting protein–glycan interactions , 2009, British journal of pharmacology.

[41]  L. Liaw,et al.  Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[42]  Youhua Liu,et al.  Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.

[43]  T. Handel,et al.  Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. , 2005, Cytokine & growth factor reviews.

[44]  T. Handel,et al.  Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. , 2005, Annual review of biochemistry.

[45]  A. Imberty,et al.  Heparan Sulfate/Heparin Oligosaccharides Protect Stromal Cell-derived Factor-1 (SDF-1)/CXCL12 against Proteolysis Induced by CD26/Dipeptidyl Peptidase IV* , 2004, Journal of Biological Chemistry.

[46]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[47]  U. V. von Andrian,et al.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.

[48]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[49]  G. Jayson,et al.  Heparan sulfate proteoglycans and cancer , 2001, British Journal of Cancer.

[50]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[51]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[52]  M. Lyon,et al.  The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.

[53]  J. Farber HuMig: a new human member of the chemokine family of cytokines. , 1993, Biochemical and biophysical research communications.

[54]  A. Billiau,et al.  Human Fibroblast Interferon for Clinical Trials: Production, Partial Purification, and Characterization , 1979, Antimicrobial Agents and Chemotherapy.

[55]  P. Proost,et al.  Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines. , 2009, Methods in enzymology.

[56]  Youhua Liu Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. , 2004, Journal of the American Society of Nephrology : JASN.

[57]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.